
-
Black Diamond Therapy Inc. NasdaqGS:BDTX Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Location: One Main Street, Cambridge, MA, 02142, United States | Website: https://www.blackdiamondtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
22.77M
Cash
98.58M
Avg Qtr Burn
-15.58M
Short % of Float
24.21%
Insider Ownership
0.62%
Institutional Own.
86.80%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BDTX-1535 Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
BDTX-1535 Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
BDTX-4933 Details Cancer | Phase 1 Update | |
BDTX-1535 Details Cancer, Glioblastoma | Phase 1 Update | |
BDTX-189 (EGFR HER2) Details Solid tumor/s, Cancer | Failed Discontinued |